TTK Healthcare Limited TTKHLTCARE NSEPHARMA
Company Overview
TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Foods, Protective Devices and Other segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripe water name; personal care products and cosmetics under the EVA name; home care products, such as scrubbers under the Good Home name; and air fresheners. The Medical Devices segment manufactures and markets artificial heart valves under the TTK Chitra name, as well as orthopedic implants and instruments for knee and hip replacements. The Protective Devices segment manufactures and markets sexual wellness products, including male contraceptives under the Skore brand name, and other allied products. The Foods segment engages in the manufacturing and marketing of food products, including papads under the Fryums name; and cereal, potato, rice, pulses, and corn-based products. The Others segment prints and publishes maps, atlases, guidebooks, and educational publications under the TTK brand name. The company was founded in 1928 and is headquartered in Chennai, India. TTK Healthcare Limited operates as a subsidiary of TT Krishnamachari & Co., Ltd.
Why Investors Should Care
Trades at a P/E of 19.0, below the sector median of 41.6.
Recent Developments
- Mar 2026 Revenue of ₹854.38 Cr (+7.1% YoY); net profit ₹65.68 Cr.
- Trailing 12 Months Year-on-year growth — revenue +7.1%, earnings -19.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.9%, profit CAGR -53.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.86% |
| 1 Year: | 7.11% |
Compounded Profit Growth
| 5 Years: | -53.17% |
| 1 Year: | -19.57% |
Stock Price Performance
| 1 Year: | -2.67% |
| 6 Months: | +29.10% |
| 3 Months: | +23.58% |
| 1 Month: | +0.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.24 · Neutral
P/E of 19.04 is below the sector median of 41.64 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -53.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TTKHLTCARE TTK Healthcare Limited NSEPHARMA | 1,100.20 | 19.04 | ₹1,554.62 Cr | 0.91% | 7.51% | 5.89% | 5.86% | -53.17% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 204.74 Cr | 190.36 Cr | 226.43 Cr | 209.30 Cr | 217.98 Cr |
| Cost of Revenue | 98.03 Cr | 87.50 Cr | 101.82 Cr | 97.62 Cr | 106.20 Cr |
| Gross Profit | 106.71 Cr | 102.85 Cr | 124.61 Cr | 111.68 Cr | 111.78 Cr |
| Operating Expenses | 101.13 Cr | 93.02 Cr | 124.12 Cr | 106.77 Cr | 102.89 Cr |
| Operating Income | 5.58 Cr | 9.84 Cr | 48.75 L | 4.92 Cr | 8.89 Cr |
| EBITDA | 25.53 Cr | 24.83 Cr | 20.61 Cr | 16.99 Cr | 32.30 Cr |
| Interest Expense | 82.33 L | 90.47 L | 76.96 L | 68.32 L | 63.76 L |
| Pretax Income | 22.59 Cr | 21.76 Cr | 17.65 Cr | 14.09 Cr | 29.53 Cr |
| Tax Provision | 5.86 Cr | 5.61 Cr | 4.65 Cr | 3.55 Cr | 7.76 Cr |
| Net Income | 16.73 Cr | 16.15 Cr | 13.00 Cr | 10.53 Cr | 21.76 Cr |
| Diluted EPS | 11.84 | 11.43 | 9.20 | 7.45 | 15.40 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 720.19 Cr | 747.64 Cr | 797.63 Cr | 854.38 Cr |
| Cost of Revenue | - | 350.32 Cr | 340.54 Cr | 371.82 Cr | 406.23 Cr |
| Gross Profit | - | 369.86 Cr | 407.10 Cr | 425.81 Cr | 448.14 Cr |
| Operating Expenses | - | 350.77 Cr | 382.11 Cr | 398.88 Cr | 430.42 Cr |
| Operating Income | - | 19.09 Cr | 24.99 Cr | 26.93 Cr | 17.72 Cr |
| EBITDA | - | 79.79 Cr | 99.11 Cr | 118.61 Cr | 93.09 Cr |
| Interest Expense | - | 5.24 Cr | 1.93 Cr | 1.95 Cr | 1.77 Cr |
| Pretax Income | - | 61.64 Cr | 84.12 Cr | 108.33 Cr | 82.56 Cr |
| Tax Provision | - | 16.97 Cr | 21.28 Cr | 26.67 Cr | 16.88 Cr |
| Net Income | - | 639.71 Cr | 62.84 Cr | 81.66 Cr | 65.68 Cr |
| Diluted EPS | 29.43 | 452.72 | 44.47 | 57.79 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 1,170.11 Cr | 1,206.30 Cr | 1,281.19 Cr | 1,328.74 Cr |
| Current Assets | - | 1,066.07 Cr | 1,077.30 Cr | 1,103.89 Cr | 1,217.90 Cr |
| Cash & Equivalents | - | 9.32 Cr | 10.96 Cr | 9.01 Cr | 21.88 Cr |
| Inventory | - | 84.51 Cr | 96.99 Cr | 108.59 Cr | 108.72 Cr |
| Receivables | - | 92.10 Cr | 86.44 Cr | 90.53 Cr | 110.66 Cr |
| Total Liabilities | - | 216.73 Cr | 205.38 Cr | 216.14 Cr | 213.89 Cr |
| Current Liabilities | - | 210.78 Cr | 201.52 Cr | 210.92 Cr | 206.23 Cr |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 27.33 Cr | 22.81 Cr | 24.22 Cr | 24.38 Cr |
| Total Equity | - | 953.38 Cr | 1,000.92 Cr | 1,065.05 Cr | 1,114.85 Cr |
| Shares Outstanding | - | 1.41 Cr | 1.41 Cr | 1.41 Cr | 1.41 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -24.81 Cr | -4.94 Cr | -3.98 Cr | -21.15 Cr |
| Investing Cash Flow | - | 31.69 Cr | 28.49 Cr | 20.10 Cr | 51.58 Cr |
| Financing Cash Flow | - | -12.43 Cr | -21.91 Cr | -18.08 Cr | -17.56 Cr |
| Capital Expenditure | - | -11.70 Cr | -10.38 Cr | -12.84 Cr | -5.80 Cr |
| Free Cash Flow | - | -36.51 Cr | -15.33 Cr | -16.82 Cr | -26.95 Cr |
| Net Change in Cash | - | -5.54 Cr | 1.64 Cr | -1.95 Cr | 12.88 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 51.4% | 54.5% | 53.4% | 52.5% |
| Operating Margin % | - | 2.7% | 3.3% | 3.4% | 2.1% |
| Net Margin % | - | 88.8% | 8.4% | 10.2% | 7.7% |
| ROE % | - | 67.1% | 6.3% | 7.7% | 5.9% |
| ROCE % | - | 2.0% | 2.5% | 2.5% | 1.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TTKHLTCARE
TTK Healthcare's (NSE:TTKHLTCARE) Problems Go Beyond Weak Profit - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPTE0xRXFiZm1RdXZCSVJuMWowNWZqMVVuV0V0ZjAwc1NnYl8zaW5iVnRmSFduWkN5emRiVEpRTDNkb2JQdWdDMGRkbTFnZjc2dFRWcEIzU1RTa1R0ZnpqbFB6ZXlnZmVhRi1ZQ1hubGFlMDhwdUVxUWQxTE85Wk1tV05DM1lBNDl2QllJMF…
TTK Healthcare Gains Marginally; Key Levels in Focus - Pairs Trade - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNZGkyeGN2cmxhUXY2aHlLMUdydTA4MWNaSG96WXFTdlhnbUFhMUxhWk1xdHZTLXBSeW80YUxFMUZFVER4X01PRndNWGZCM2RvZlB4WVo3dWdMcV9LeGtKcHNCSXlOWTRqdGhBTUhxZ1NXd1ZiUHlmSVZjeDd5NTVrQ0JaSkJ2b1lFbXQyWE…
TTK Healthcare Edges Higher: Navigating Support and Resistance Levels - McClellan Oscillator - siam.in
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNNkpITWZpSkFoejF3TlBYaDdxU2sxTzR2VzFNeDBMcmV5eWhRRFctS0VFdUl2M0Z1VVpoejBILWFjT1Z0MVBoMjhyc3hUU0JtamF4Y0w2bm9zVERXNWQwVFdLRTRHY1h6anoyQ2J4eEdnZFdtQTMyTFM5djNINnd6a2ppb3hyY1I5bkRkOE…
TTKHLTCARE Mar 2026 Earnings: Revenue at ₹218 Crore, EPS of ₹15.4 - EBITDA Margin Trends - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQTDBFcE95X05wVXpsU2hPbTJueEFqN0F4Q0QwQ0YwYkNwRThfckpNWHVQd2ItSG9IcEpLOTBzdzR5UFFQOHp6OVlpemdaUnFwbmpFZjVVNnVGdUd5NUR6Z1pXSl8ySS1MSmc1THUwbDdIWmtLdGhxcHBGeFJFTlkxQy1kNmxIQ25VREJYY3…
TTK Healthcare (TTKHLTCARE.NS) Gains Nearly 4% on the NSE – Support and Resistance Levels in Focus - ETF AUM Growth - siam.in
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNOV9mZkhaQzRRY3lwbjdCRVB5ZmxjUDVfemdmdFlmaHJ1aFdBbmN5eV9ybXpkdjdTejhtcnI1dXp2QmdqX0Rvd2hILUR5MGNtc2JRYWNTY3ppV1JTQ0Q4VDJIV0Y5SFpFZ21QNXJMZzVJc25XQ1l1bWNUQnVXemJqbVlvQnNLOEFidnFSQ2…
TTK Healthcare Stock Edges Higher, Trading Between Key Support and Resistance Levels - MA Cross Alert - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNM2ZlTkplR285U0JlcVpxLTBrVnRzQ2ZzVEtHeEdCUlFpaUVaMXM5cDFMUzFpTF9HMXFCUFEtejhjWmJNUDctM241c1BzMlA4VzJnenlWSTdYTk4zMi02bDhHMFV5T0lHMk1GalhxeURhbTljTmIyeVJ1NVYtUEo1LXhTUE1CMkZEbUUzNH…
TTKHLTCARE — Frequently Asked Questions
What is the current share price of TTK Healthcare Limited (TTKHLTCARE)?
As of 2026-09-08 04:53 IST, TTK Healthcare Limited (TTKHLTCARE) trades at ₹1,100.20 on NSE. Its 52-week range is ₹732.12 to ₹1,180.53.
What is the market capitalisation of TTKHLTCARE?
TTK Healthcare Limited (TTKHLTCARE) has a market capitalisation of ₹1,554.62 Cr on NSE.
What is the P/E ratio of TTKHLTCARE?
TTKHLTCARE trades at a trailing price-to-earnings (P/E) ratio of 19.04. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 1.37.
Does TTKHLTCARE pay a dividend?
TTK Healthcare Limited (TTKHLTCARE) currently offers a dividend yield of 0.91%.
What is the return on equity (ROE) of TTKHLTCARE?
TTKHLTCARE has a return on equity (ROE) of 5.89%. Its return on capital employed (ROCE) is 7.51%.
Is TTKHLTCARE a good stock to buy?
This page provides a data-driven analysis of TTK Healthcare Limited (TTKHLTCARE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.